HE 3286

Drug Profile

HE 3286

Alternative Names: HE3286; Triolex

Latest Information Update: 22 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hollis-Eden Pharmaceuticals
  • Developer Harbor Therapeutics; The Michael J. Fox Foundation for Parkinson's Research
  • Class Anti-inflammatories; Antiepileptic drugs; Antihyperglycaemics; Hormones; Obesity therapies; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase modulators; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cystic fibrosis

Highest Development Phases

  • Suspended Cystic fibrosis; Epilepsy; Parkinson's disease; Rheumatoid arthritis; Type 2 diabetes mellitus; Ulcerative colitis; Uveitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 20 Jan 2012 Preclinical trials in Uveitis in USA (unspecified route)
  • 01 Mar 2011 HE 3286 is still in phase I/II development for Rheumatoid arthritis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top